20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Exploring the Pharmaceutical Potential: Bosutinib for Solid Tumors and Beyond

While Bosutinib (CAS 380843-75-4) is well-established for its role in treating certain types of leukemia, its pharmaceutical potential extends significantly into the realm of solid tumors. As a dual Src/Abl inhibitor, Bosutinib targets key signaling pathways implicated in the growth, migration, and invasion of cancer cells across a spectrum of malignancies.

The Src kinase family, which Bosutinib potently inhibits, is often overexpressed or hyperactivated in many solid tumors, including breast, lung, colon, and ovarian cancers. This aberrant activity contributes to tumor progression, metastasis, and resistance to conventional therapies. By targeting Src, Bosutinib offers a promising avenue for developing novel treatment strategies for these challenging cancers. Research into Bosutinib's efficacy in solid tumor models is actively exploring its ability to suppress tumor growth and prevent the spread of cancer cells.

The development of Bosutinib as a pharmaceutical chemical involves rigorous testing and optimization. The ability to purchase Bosutinib for research allows scientists to delve deeper into its mechanisms of action in various cancer types. NINGBO INNO PHARMCHEM CO.,LTD. plays a crucial role in this scientific endeavor by providing access to high-quality Bosutinib, enabling researchers to conduct critical studies. This includes investigating synergistic effects when combined with other chemotherapeutic agents or targeted therapies, further expanding the therapeutic applications of this versatile compound.

The journey of Bosutinib from a targeted therapy for leukemia to a potential treatment for solid tumors highlights the dynamic nature of pharmaceutical research. Its dual kinase inhibition profile and demonstrated antiproliferative activity make it a compound of significant interest for oncological drug development. NINGBO INNO PHARMCHEM CO.,LTD. is proud to support this research by ensuring the availability of reliable Bosutinib for scientific exploration.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Bosutinib: A Deep Dive into its Dual Kinase Inhibition and Antiproliferative Activity

Next: Understanding the Bosutinib Mechanism: A Key Pharmaceutical Chemical for Targeted Therapy

All Rights Reserved